Gene therapy, combined with autologous hematopoietic stem cell (HSC) transplantation, has the potential to treat a variety of nonmalignant, congenital hematologic disorders. Gene transfer to HSC followed by transplantation of those HSC into fully myeloablated subjects can produce high levels of gene-corrected blood cells in vivo. Unfortunately, intensive conditioning regimens are associated with significant toxicity. As a result, submyeloablative conditioning has been proposed as an alternative transplantation method. Transplantation of transduced HSC into submyeloablated syngeneic hosts, however, is less efficient than transplantation of transduced HSC into fully ablated hosts. This laboratory recently observed that marrow cells cultured ex vivo during gene transfer acquire an engraftment defect that is evident in submyeloablated hosts. Because most transduction protocols involve ex vivo culture, this engraftment defect is likely to impede efforts to achieve clinically relevant levels of gene-corrected blood cells in the submyeloablative setting. The current understanding of the mechanisms governing HSC self-renewal and how these processes are altered during ex vivo culture are incomplete;a better understanding of both are necessary for improved clinical outcomes. The experiments proposed in this application will determine factors important for the engraftment of transduced HSC in two models of submyeloablative conditioning for murine hosts, low dose radiation and a novel antimetabolite-based regimen. We hypothesize that the manipulations required for HSC transduction produce changes in HSC function that negatively impact engraftment in submyeloablated hosts. We plan to test this hypothesis, in murine syngeneic and xenogeneic human-NOD/SCID mouse models, using the following specific aims: 1) Determine the extent to which ex vivo transduction of HSC under optimized conditions improves engraftment in submyeloablated hosts;2) Determine the molecular mechanism by which ex vivo transduction impairs HSC engraftment in submyeloablated hosts;and 3) Determine the capacity of non-HSC populations present in the marrow to enhance long-term engraftment of transduced HSC in submyeloablated hosts. The findings from these studies, together with the technical expertise and scientific direction acquired from further mentored training during this award period, will form the foundation for future independent investigations into mechanisms responsible for maintaining human HSC self-renewal and engraftment in the setting of hematopoietic cell gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08HL075253-05
Application #
7664451
Study Section
Special Emphasis Panel (ZHL1-CSR-B (M2))
Program Officer
Werner, Ellen
Project Start
2005-08-01
Project End
2010-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
5
Fiscal Year
2009
Total Cost
$133,378
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Pediatrics
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Wang, Haiyan; Cai, Shanbao; Ernstberger, Aaron et al. (2013) Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways. Clin Cancer Res 19:2699-709
Alge, Daniel L; Goebel, W Scott; Chu, Tien-Min Gabriel (2013) Effects of DCPD cement chemistry on degradation properties and cytocompatibility: comparison of MCPM/ýý-TCP and MCPM/HA formulations. Biomed Mater 8:025010
Alge, Daniel L; Bennett, Jeffrey; Treasure, Trevor et al. (2012) Poly(propylene fumarate) reinforced dicalcium phosphate dihydrate cement composites for bone tissue engineering. J Biomed Mater Res A 100:1792-802
Alge, Daniel L; Goebel, W Scott; Chu, Tien-Min Gabriel (2012) In vitro degradation and cytocompatibility of dicalcium phosphate dihydrate cements prepared using the monocalcium phosphate monohydrate/hydroxyapatite system reveals rapid conversion to HA as a key mechanism. J Biomed Mater Res B Appl Biomater 100:595-602
Cai, Shanbao; Wang, Haiyan; Bailey, Barbara et al. (2011) Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. Clin Cancer Res 17:2195-206
Alge, Daniel L; Zhou, Dan; Adams, Lyndsey L et al. (2010) Donor-matched comparison of dental pulp stem cells and bone marrow-derived mesenchymal stem cells in a rat model. J Tissue Eng Regen Med 4:73-81
Wyss, Brandon K; Donnelly, Abigail F W; Zhou, Dan et al. (2009) Enhanced homing and engraftment of fresh but not ex vivo cultured murine marrow cells in submyeloablated hosts following CD26 inhibition by Diprotin A. Exp Hematol 37:814-23
Sadat, M A; Dirscherl, S; Sastry, L et al. (2009) Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation. Gene Ther 16:1452-64
Li, Yan; Chen, Shi; Yuan, Jin et al. (2009) Mesenchymal stem/progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg-/- mice in vivo. Blood 113:2342-51
Woods, Erik J; Perry, Brandon C; Hockema, J Jeffrey et al. (2009) Optimized cryopreservation method for human dental pulp-derived stem cells and their tissues of origin for banking and clinical use. Cryobiology 59:150-7

Showing the most recent 10 out of 14 publications